The agreement will create a strong global growth platform for Sandoz, which is the pharmaceuticals division of Novartis. Sandoz will use its leading position both in the US generics sector and its presence in over 130 countries worldwide to expand Fougera’s existing sales base and bring its broad dermatology portfolio to new markets around the world.
Jeff George, Global Head of Sandoz said “The addition of Fougera’s leading portfolio further strengthens Sandoz’s differentiated products strategy and improves our ability to help patients and customers around the world by providing easier access to high quality, affordable dermatological medicines. Fougera brings us valuable technical capabilities in the area of topical dermatological products, particularly in the development and manufacturing of semi-solid forms such as creams and ointments,”
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates